Table 1.
Prevalence of Frailty and Associated Outcome as Measured by the RAI-C, RAI-A, and mFI
| Outcomea | 0–15 | 16–25 | 26–35 | ≥36 | Overall |
|---|---|---|---|---|---|
| RAI-C score | |||||
| No. in cohort | 5250 | 1178 | 293 | 82 | 6803 |
| Proportion of cohort, % | 77.2 | 17.3 | 4.3 | 1.2 | 100 |
| Mortality, No. (%) | |||||
| 30-d (n = 6803) | 14 (0.3) | 6 (0.5) | 5 (1.7) | 4 (4.9) | 29 (0.4) |
| 180-d (n = 6419) | 43 (0.9) | 35 (3.3) | 23 (8.4) | 13 (17.3) | 114 (1.8) |
| 365-d (n = 5959) | 74 (1.6) | 71 (7.3) | 43 (17.1) | 19 (26.8) | 207 (3.5) |
| RAI-A score | |||||
| No. in cohort | 2438 | 267 | 60 | 20 | 2785 |
| Proportion of cohort, % | 87.5 | 9.6 | 2.2 | 0.7 | 100 |
| Mortality, No. % | |||||
| 30-d | 3 (0.1) | 3 (1.1) | 0 | 1 (5.0) | 7 (0.3) |
| 180-d | 19 (0.8) | 15 (5.6) | 4 (6.7) | 2 (10.0) | 40 (1.4) |
| 365-d | 46 (1.9) | 24 (9.0) | 10 (16.7) | 3 (15.0) | 83 (3.0) |
| Complications, No. (%) | |||||
| Any except SSI and UTI | 112 (4.6) | 30 (11.2) | 8 (13.3) | 5 (25.0) | 155 (5.6) |
| Clavien-Dindo IV | 60 (2.5) | 15 (5.6) | 2 (3.3) | 3 (15.0) | 80 (2.9) |
| mFI score | <0.19 | 0.27 | 0.36 | >0.37 | Overall |
| No. in cohort | 705 | 207 | 77 | 32 | 1021 |
| Proportion of cohort, % | 69.0 | 20.3 | 7.5 | 3.1 | 100.0 |
| Mortality, No. (%) | |||||
| 30-d | 0 | 0 | 1 (1.3) | 1 (3.1) | 2 (0.2) |
| 180-d | 4 (0.6) | 4 (1.9) | 2 (2.6) | 6 (18.8) | 16 (1.6) |
| 365-d | 10 (1.4) | 12 (5.8) | 3 (3.9) | 7 (21.9) | 32 (3.1) |
| Complications, % | |||||
| Any except SSI and UTI | 33 (4.7) | 13 (6.3) | 12 (15.6) | 8 (25.0) | 66 (6.5) |
| Clavien-Dindo IV | 26 (3.7) | 7 (3.4) | 8 (10.4) | 7 (21.9) | 48 (4.7) |
Abbreviations: mFI, Modified Frailty Index; RAI, Risk Analysis Index; RAI-A, Administrative Risk Analysis Index; RAI-C, Clinical Risk Analysis Index; SSI, superficial site infection; UTI, urinary tract infection.
a
Outcome data were complete for all patients with RAI-A and mFI scores. Mortality data for 180 and 365 days for the RAI-C cohort were somewhat smaller owing to length of follow-up with 6419 and 5959 patients, respectively.